Core Viewpoint - The stock of Baiaosaitu-B (02315) has seen a significant increase, rising over 5% and reaching a price of 36.08 HKD, with a trading volume of 27.5841 million HKD. The inclusion of Baiaosaitu in the Hong Kong Stock Connect list marks a significant milestone for the company, allowing mainland investors access to its shares starting December 24, 2025 [1][1][1]. Group 1 - The Shanghai Stock Exchange and Shenzhen Stock Exchange have announced the inclusion of Baiaosaitu in the Hong Kong Stock Connect stock list, effective December 24, 2025 [1][1][1]. - This inclusion represents an important milestone in the company's strategy to establish a dual capital market platform, referred to as "A+H" [1][1][1]. - The stock price increase reflects positive market sentiment and investor interest following the announcement [1][1][1]. Group 2 - Huafu Securities has issued a report indicating that the company's antibody development is beginning to yield results, driving significant performance growth [1][1][1]. - The report highlights the company's high growth potential and strong barriers to entry, with a solid foundation in preclinical animal and pharmacological evaluations [1][1][1]. - The antibody development business is entering a phase of performance realization, complemented by promising potential in new drug pipelines, leading to an initial "Buy" rating [1][1][1].
港股异动 | 百奥赛图-B(02315)再涨超5% 公司近期正式进入港股通名单 机构称千鼠万抗开始兑现